Balneophototherapy for neurodermatitis will be reimbursed in Germany

10

Sep 2020

From October 1, 2020, balneophototherapy can also be used for patients with moderate to severe neurodermatitis and billed via the EBM (German Uniform Evaluation Standard). So far, dermatologists have only been able to use the method for patients with psoriasis.

For this purpose, the Evaluation Committee has adjusted the fee order item (GOP) 10350 "Balneophototherapy in accordance with the Guideline of the Federal Joint Committee (No. 15 of Annex I "Recognized examination or treatment methods" of the Guideline for Methods of contracted medical care) and in accordance with the quality assurance agreement for balneophototherapy in accordance with §135 (2) SGB V, including costs", evaluated with a tariff of €43.73. The Federal Joint Committee (G-BA) decided to include this treatment option to contractual medical care on March 20, 2020.

Balneophototherapy can be provided as photo-brine therapy (salt bath combined with UVB rays) or as bath PUVA (psoralen combined with UVA rays).

The frequency of treatment should be three (3) to five (5) applications per week and is limited to a maximum of thirty-five (35) individual applications per treatment cycle. A new treatment cycle can start no earlier than six (6) months after completion of a previous treatment cycle.

Dermatologists, who carry out the treatment, require approval from their statutory health insurance association according to the quality assurance agreement for balneophototherapy.

The full details in German can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

09

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more